The Role of PACAP in the Regulation of Body Temperature

Garami, András; Pákai, Eszter; Rumbus, Zoltán; Solymár, Margit

doi:10.1007/978-3-319-35135-3_15

Cited by 5 publications

(7 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PACAP occurs at highest concentrations in the nervous system, where it functions as a neuromodulatory and neurotransmitter peptide. In the nervous system, PACAP acts, amongst others, on hypothalamic hormone release and hypothalamo-hypophyseal hormonal regulatory pathways [ 3 , 4 ], on central thermoregulatory and feeding routes [ 5 , 6 , 7 , 8 ], on neurogenesis [ 9 ] and on cognitive performance [ 10 , 11 , 12 ]. Of special importance is the action of PACAP on neuronal proliferation, differentiation and migration, whereby the peptide has significant effects in the development of the nervous system [ 13 , 14 ].…”

Section: General Overviewmentioning

confidence: 99%

“…It functions as a neurotransmitter and neuromodulator [ 34 ] and affects glial functions [ 14 ]. PACAP affects several physiological actions in the adult brain and is involved in complex behavioral processes, such as feeding, motor functions and thermoregulation [ 2 , 3 , 5 , 24 ]. PACAP is also involved in cognitive performance, fear and anxiety [ 12 , 14 ].…”

Section: Neuroprotective Effects Of Pacapmentioning

confidence: 99%

See 1 more Smart Citation

Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair

Rivnyak

Kiss

Tamás

et al. 2018

IJMS

View full text Add to dashboard Cite

Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with widespread occurrence and diverse biological effects. Among its several different effects, of special importance is the action of PACAP on neuronal proliferation, differentiation and migration, and neuroprotection. The neuroprotective mechanism of PACAP is both direct and indirect, via neuronal and non-neuronal cells. Several research groups have performed transcriptomic and proteomic analysis on PACAP-mediated genes and proteins. Hundreds of proteins have been described as being involved in the PACAP-mediated neuroprotection. In the present review we summarize the few currently available transcriptomic data potentially leading to the proteomic changes in neuronal development and protection. Proteomic studies focusing on the neuroprotective role of PACAP are also reviewed and discussed in light of the most intriguing and promising effect of this neuropeptide, which may possibly have future therapeutic potential.

show abstract

Section: General Overviewmentioning

confidence: 99%

Section: Neuroprotective Effects Of Pacapmentioning

confidence: 99%

Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair

Rivnyak

Kiss

Tamás

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…PACAP exists in two biologically active forms, PACAP1-27 and PACAP1-38. PACAP has a wide variety of diverse biological effects in different cells and tissues, from thermoregulatory effects [1], actions on cardiac excitability [2], thyroid gland functions [3], chondrogenesis [4] and muscle contraction [5]. Among the well-established and most intensively studied actions are PACAP’s neurotrophic and neuroprotective effects.…”

Section: Introductionmentioning

confidence: 99%

Passage through the Ocular Barriers and Beneficial Effects in Retinal Ischemia of Topical Application of PACAP1-38 in Rodents

Werling

Banks

Salameh

et al. 2017

IJMS

View full text Add to dashboard Cite

The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has two active forms, PACAP1-27 and PACAP1-38. Among the well-established actions are PACAP’s neurotrophic and neuroprotective effects, which have also been proven in models of different retinopathies. The route of delivery is usually intravitreal in studies proving PACAP’s retinoprotective effects. Recently, we have shown that PACAP1-27 delivered as eye drops in benzalkonium-chloride was able to cross the ocular barriers and exert retinoprotection in ischemia. Since PACAP1-38 is the dominant form of the naturally occurring PACAP, our aim was to investigate whether the longer form is also able to cross the barriers and exert protective effects in permanent bilateral common carotid artery occlusion (BCCAO), a model of retinal hypoperfusion. Our results show that radioactive PACAP1-38 eye drops could effectively pass through the ocular barriers to reach the retina. Routine histological analysis and immunohistochemical evaluation of the Müller glial cells revealed that PACAP1-38 exerted retinoprotective effects. PACAP1-38 attenuated the damage caused by hypoperfusion, apparent in almost all retinal layers, and it decreased the glial cell overactivation. Overall, our results confirm that PACAP1-38 given in the form of eye drops is a novel protective therapeutic approach to treat retinal diseases.

show abstract

“…Based on the current data, the PACAPergic system appears to be implicated in multiple loci that may contribute, either directly or indirectly, to the development of sudden infant death (Figure 2), suggesting that alterations in its function, whether genetic, in expression, or translation, could potentially render the infant 'vulnerable' in this context. Dozens of in vivo data highlight the role of PACAP in metabolism [53], thermal regulation [54,55], cardiovascular adaptation [56,57], central and peripheral control of breathing [58][59][60], responses to stress [55,[61][62][63][64], sleep-wake regulation [65,66] and immunohomeostasis [67]. The lessons we have learnt from PACAP or PAC1R knockout models exhibit multiple similarities with human data from SIDS case studies:…”

Section: Discussionmentioning

confidence: 97%

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and Sudden Infant Death Syndrome: A Potential Model for Investigation

Tóth,

Simon,

Reglődi

2023

IJMS

View full text Add to dashboard Cite

Sudden infant death syndrome (SIDS) represents a significant cause of post-neonatal mortality, yet its underlying mechanisms remain unclear. The triple-risk model of SIDS proposes that intrinsic vulnerability, exogenous triggers, and a critical developmental period are required for SIDS to occur. Although case–control studies have identified potential risk factors, no in vivo model fully reflects the complexities observed in human studies. Pituitary adenylate cyclase-activating polypeptide (PACAP), a highly conserved neuropeptide with diverse physiological functions, including metabolic and thermal regulation, cardiovascular adaptation, breathing control, stress responses, sleep–wake regulation and immunohomeostasis, has been subject to early animal studies, which revealed that the absence of PACAP or its specific receptor (PAC1 receptor: PAC1R) correlates with increased neonatal mortality similar to the susceptible period for SIDS in humans. Recent human investigations have further implicated PACAP and PAC1R genes as plausible contributors to the pathomechanism of SIDS. This mini-review comprehensively synthesizes all PACAP-related research from the perspective of SIDS and proposes that PACAP deficiency might offer a promising avenue for studying SIDS.

show abstract

The Role of PACAP in the Regulation of Body Temperature

Cited by 5 publications

References 106 publications

Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair

Review on PACAP-Induced Transcriptomic and Proteomic Changes in Neuronal Development and Repair

Passage through the Ocular Barriers and Beneficial Effects in Retinal Ischemia of Topical Application of PACAP1-38 in Rodents

Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) and Sudden Infant Death Syndrome: A Potential Model for Investigation

Contact Info

Product

Resources

About